Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  • Jiménez, Isabel|||0000-0002-5144-861X
  • Tazón-Vega, Bárbara|||0000-0003-4513-5104
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Carabia, Júlia
  • Valdés-Mas, Rafael
  • Munuera, Magdalena
  • Puigdefàbregas, Lluís
  • Parra, Genís
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Terol, María José
  • García-Marco, José Antonio
  • Crespo, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a small fraction of patients, suggesting that CLL progression is not mainly driven by dynamic clonal evolution. In order to shed light on mechanisms that lead to CLL progression, we investigated longitudinal changes in both the genetic and immunological scenarios. We performed genetic and immunological longitudinal analysis using paired primary samples from untreated CLL patients that underwent clinical progression (sampling at diagnosis and progression) and from patients with stable disease (sampling at diagnosis and at long-term asymptomatic follow-up). Molecular analysis showed limited and non-recurrent molecular changes at progression, indicating that clonal evolution is not the main driver of clinical progression. Our analysis of the immune kinetics found an increasingly dysfunctional CD8 + T cell compartment in progressing patients that was not observed in those patients that remained asymptomatic. Specifically, terminally exhausted effector CD8 + T cells (T-bet dim/- Eomes hi PD1 hi) accumulated, while the the co-expression of inhibitory receptors (PD1, CD244 and CD160) increased, along with an altered gene expression profile in T cells only in those patients that progressed. In addition, malignant cells from patients at clinical progression showed enhanced capacity to induce exhaustion-related markers in CD8 + T cells ex vivo mainly through a mechanism dependent on soluble factors including IL-10. Altogether, we demonstrate that the interaction with the immune microenvironment plays a key role in clinical progression in CLL, thereby providing a rationale for the use of early immunotherapeutic intervention. The online version contains supplementary material available at 10.1186/s40364-021-00290-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Medina, Daniel
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Lu, Junyan
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Carabia, Júlia
  • Boix, Joan
  • Tazón-Vega, Barbara
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • González, Marcos
  • Zenz, Thorsten|||0000-0001-7890-9845
  • Crespo Maull, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P <.001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P =.007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P <.001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P <.001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression-based assay with prognostic implications in CLL.